Jennerex Appoints Gregory Schafer as CFO
Jennerex, a clinical-stage cancer biotherapeutics company, has appointed Gregory Schafer as senior vice president (SVP) and chief financial officer (CFO). He will be responsible for the company’s finance, accounting, planning, investor relations and treasury functions.
Schafer brings more than 20 years of broad functional and strategic leadership expertise to Jennerex and has raised over US$600m in public and private transactions to fund biotechnology product development and commercialisation activities. Most recently, he served as CFO of Onyx Pharmaceuticals, where he was responsible for finance, accounting, risk management, and strategic and operational planning.
Prior to Onyx, he served as CFO and vice president of finance for Cerus Corporation, where he played a key role in transitioning the company from early-stage development to a commercial enterprise with an approved product. Prior to Cerus, Schafer worked as a management consultant for Deloitte and Touche, and as an engineer specialising in biologics manufacturing. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company. He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.